H. Shimizu

614 total citations
25 papers, 479 citations indexed

About

H. Shimizu is a scholar working on Molecular Biology, Pharmacology and Neurology. According to data from OpenAlex, H. Shimizu has authored 25 papers receiving a total of 479 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Pharmacology and 5 papers in Neurology. Recurrent topics in H. Shimizu's work include Amyotrophic Lateral Sclerosis Research (5 papers), Parkinson's Disease Mechanisms and Treatments (4 papers) and Analytical Methods in Pharmaceuticals (4 papers). H. Shimizu is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (5 papers), Parkinson's Disease Mechanisms and Treatments (4 papers) and Analytical Methods in Pharmaceuticals (4 papers). H. Shimizu collaborates with scholars based in Japan, United States and Italy. H. Shimizu's co-authors include K. Christmann, G. Ertl, Kaori Koga, T Harada, Kan Tanaka, Yoshinobu Nakamaru, Yukiko Nishimura, Verna Frasca, Rowena G. Matthews and Lawrence F. Courtney and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Medicinal Chemistry and Journal of Catalysis.

In The Last Decade

H. Shimizu

25 papers receiving 459 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H. Shimizu Japan 11 180 144 101 78 47 25 479
Hsiang‐Wen Chen Taiwan 12 89 0.5× 164 1.1× 166 1.6× 17 0.2× 9 0.2× 17 552
Abdulkadır Kocak Türkiye 13 121 0.7× 112 0.8× 72 0.7× 58 0.7× 2 0.0× 42 401
Dimitris Dellis Greece 13 89 0.5× 71 0.5× 136 1.3× 177 2.3× 3 0.1× 19 534
Lixin Zhou China 13 94 0.5× 39 0.3× 103 1.0× 12 0.2× 79 1.7× 64 637
Shuping Yuan China 14 185 1.0× 50 0.3× 112 1.1× 58 0.7× 2 0.0× 38 506
Myung Won Lee South Korea 16 163 0.9× 133 0.9× 152 1.5× 17 0.2× 2 0.0× 45 769
Saurabh Mishra India 14 111 0.6× 60 0.4× 120 1.2× 13 0.2× 3 0.1× 57 531
Hiroshi Akimoto Japan 17 37 0.2× 38 0.3× 314 3.1× 9 0.1× 68 1.4× 76 902
Shoji Kudo Japan 12 276 1.5× 9 0.1× 48 0.5× 12 0.2× 19 0.4× 44 602
Brian H. Robinson United Kingdom 12 75 0.4× 48 0.3× 186 1.8× 13 0.2× 2 0.0× 27 491

Countries citing papers authored by H. Shimizu

Since Specialization
Citations

This map shows the geographic impact of H. Shimizu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Shimizu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Shimizu more than expected).

Fields of papers citing papers by H. Shimizu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Shimizu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Shimizu. The network helps show where H. Shimizu may publish in the future.

Co-authorship network of co-authors of H. Shimizu

This figure shows the co-authorship network connecting the top 25 collaborators of H. Shimizu. A scholar is included among the top collaborators of H. Shimizu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Shimizu. H. Shimizu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shimizu, H., Michael A. Tortorici, Kei Ogawa, et al.. (2024). First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor. Clinical and Translational Science. 17(8). e70000–e70000. 11 indexed citations
2.
Shimizu, H., Yukiko Nishimura, Makoto Akimoto, et al.. (2023). Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis. Clinical Therapeutics. 45(12). 1251–1258. 6 indexed citations
3.
4.
Shimizu, H., et al.. (2022). Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants. Clinical Therapeutics. 44(12). 1552–1565. 2 indexed citations
5.
Shimizu, H., et al.. (2022). Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study. Clinical Pharmacology in Drug Development. 12(1). 77–84. 3 indexed citations
6.
Yoshida, Kosuke, Hidenori Yasuhara, Yuka Ikenaga, et al.. (2021). Prediction of human pharmacokinetics for low‐clearance compounds using pharmacokinetic data from chimeric mice with humanized livers. Clinical and Translational Science. 15(1). 79–91. 5 indexed citations
7.
Shimizu, H., Yukiko Nishimura, Kaori Yoshida, et al.. (2021). Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects. Clinical Pharmacology in Drug Development. 10(10). 1188–1197. 18 indexed citations
8.
9.
Shimizu, H., Shinsuke Inoue, Yoshinobu Nakamaru, et al.. (2020). A Randomized, Single‐Blind, Placebo‐Controlled, 3‐Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects. Clinical Pharmacology in Drug Development. 10(1). 46–56. 5 indexed citations
10.
Sasaki, Wataru, et al.. (2018). Discovery of Novel Pyrazole-Based Selective Aldosterone Synthase (CYP11B2) Inhibitors: A New Template to Coordinate the Heme-Iron Motif of CYP11B2. Journal of Medicinal Chemistry. 61(13). 5594–5608. 18 indexed citations
11.
12.
Ikebuchi, Yuki, H. Shimizu, Kousei Ito, et al.. (2012). Ursodeoxycholic acid stimulates the formation of the bile canalicular network. Biochemical Pharmacology. 84(7). 925–935. 5 indexed citations
13.
Miyazaki, Shohei, et al.. (2010). Structures of the SEp22 dodecamer, a Dps-like protein fromSalmonella entericasubsp.entericaserovar Enteritidis. Acta Crystallographica Section F Structural Biology and Crystallization Communications. 67(1). 17–22. 11 indexed citations
14.
Koga, Kaori, T Harada, H. Shimizu, & Kan Tanaka. (2005). Bacterial luciferase activity and the intracellular redox pool in Escherichia coli. Molecular Genetics and Genomics. 274(2). 180–188. 35 indexed citations
15.
Kawano, Hiroyuki, et al.. (1996). Temperature-programmed desorption of positive ions and neutral molecules from alkali halide layers deposited on a metal surface. Applied Surface Science. 100-101. 174–178. 8 indexed citations
16.
Shimizu, H., H. Noguchi, & Kazuaki Uno. (1992). Variation of pharmacokinetics after oral administration of slow-release metoprolol tablets and pharmacogenetic considerations.. PubMed. 42(6). 802–6. 2 indexed citations
17.
Shimizu, H., et al.. (1991). The Influence of food on the bioavailability of slow-release metoprolol tartrate 120mg tablet in healthy volunteers and serum protein binding of metoprolol.. Drug Metabolism and Pharmacokinetics. 6(4). 573–578. 1 indexed citations
18.
Shimizu, H., et al.. (1991). Bioavailability of slow-release metoprolol tartrate 120mg tablet in comparison with conventional metoprolol tartrate 40mg tablets in healthy volunteers.. Drug Metabolism and Pharmacokinetics. 6(4). 567–572. 1 indexed citations
19.
Shimizu, H., Kohei Taniguchi, Masayasu Sugiyama, & Takashi Kanno. (1990). Rapid enzymatic analysis of plasma for tyrosine.. PubMed. 36(1). 32–5. 14 indexed citations
20.
Christmann, K., G. Ertl, & H. Shimizu. (1979). The growth and structure of copper films on (0001) ruthenium surfaces. Thin Solid Films. 57(2). 247–252. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hsiang‐Wen Chen Breakdown of academic impact, for papers by Abdulkadır Kocak Breakdown of academic impact, for papers by Dimitris Dellis Breakdown of academic impact, for papers by Lixin Zhou Breakdown of academic impact, for papers by Shuping Yuan Breakdown of academic impact, for papers by Myung Won Lee Breakdown of academic impact, for papers by Saurabh Mishra Breakdown of academic impact, for papers by Hiroshi Akimoto Breakdown of academic impact, for papers by Shoji Kudo Breakdown of academic impact, for papers by Brian H. Robinson
Rankless by CCL
2026